MAP2K1 Mutation in Colorectal Cancer Patients: Therapeutic Challenge Using Patient-Derived Tumor Cell Lines.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• The MAP2K1 K57T mutation confers resistance to EGFR, BRAF, and MEK inhibitors in metastatic colorectal cancer (CRC).
• Overcoming therapeutic resistance is crucial for improving treatment outcomes in metastatic CRC.

Purpose of the Study:

• To investigate therapeutic options for overcoming acquired resistance mediated by MAP2K1 mutations in BRAF-mutant CRC.
• To evaluate the efficacy of combination therapies in patient-derived tumor cells (PDCs) harboring the MAP2K1 K57T mutation.

Main Methods:

• Established patient-derived tumor cells (PDCs) from metastatic lesions of a BRAF-mutant CRC patient resistant to combined BRAF and EGFR inhibitors.
• Performed cell viability assays (MTT proliferation assays) to assess responses to monotherapies and combination treatments.

Main Results:

• Monotherapy with cetuximab, sorafenib, or AZD6244 did not suppress PDC viability.
• Combination treatment with sorafenib (BRAF inhibitor) and AZD6244 (MEK inhibitor) demonstrated synergistic anti-tumor effects.
• Combination of cetuximab (EGFR inhibitor) and AZD6244 did not inhibit PDC proliferation.

Conclusions:

• Combination therapy with BRAF and MEK inhibitors represents a potential novel treatment strategy for MAP2K1 K57T-mutant CRC.
• Findings may guide treatment decisions for CRC patients with acquired resistance to EGFR inhibitors.